Allogene Therapeutics (ALLO) Gains from Investment Securities (2018 - 2026)

Allogene Therapeutics has disclosed Gains from Investment Securities across 9 years of filings, most recently posting -$84000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$84000.0, up 80.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $341000.0 (up 110.46% YoY), and the FY2024 annual result was -$4.3 million, down 161.13% from the prior year.
• Gains from Investment Securities came in at -$84000.0 for Q1 2026 at Allogene Therapeutics, up from -$1.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $28.2 million in Q4 2022 to a low of -$6.7 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $100000.0 (2023), against an average of $2.5 million.
• Peak annual rise in Gains from Investment Securities reached 3754.0% in 2024, while the deepest fall reached 3111.11% in 2024.
• Allogene Therapeutics' Gains from Investment Securities stood at $28.2 million in 2022, then tumbled by 75.13% to $7.0 million in 2023, then slumped by 195.54% to -$6.7 million in 2024, then jumped by 77.53% to -$1.5 million in 2025, then surged by 94.41% to -$84000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$84000.0 (Q1 2026), -$1.5 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.